AGY - ALLERGY THERAPEUTICS - Share Chat
Allergy Therapeutics plc is a UK-based biopharmaceutical company focused on the development and commercialisation of allergen-specific immunotherapies for the diagnosis and treatment of allergies. Listed on AIM, the company offers a portfolio of subcutaneous (SCIT) and sublingual (SLIT) allergy vaccines, with established sales across Europe. A key part of its strategy involves advancing its novel peanut allergy vaccine candidate, PQ, leveraging its virus-like particle (VLP) platform. While the company has a strong scientific foundation and a promising pipeline, it has recently navigated significant financial challenges, leading to various fundraising initiatives and a comprehensive strategic review exploring options including asset divestment or a sale of the entire business to secure its long-term future and fund its R&D.
Chat about ALLERGY THERAPEUTICS
Allergy Therapeutics (AGY): What's the outlook?
With the recent fundraising and share consolidation, plus ongoing progress with the VLP Peanut trial, there's certainly a lot to discuss with AGY. What are your thoughts on their current position and future prospects? Are you holding, buying, or watching from the sidelines? Let's hear your views!